<DOC>
	<DOCNO>NCT00545688</DOCNO>
	<brief_summary>This 4 arm study evaluate efficacy safety 4 neoadjuvant treatment regimen female patient locally advance , inflammatory early stage HER2 positive breast cancer . Before surgery , patient randomize one 4 treatment arm , receive 4 cycle ) Herceptin + docetaxel b ) Herceptin + docetaxel + pertuzumab c ) Herceptin + pertuzumab 4 ) pertuzumab + docetaxel . Pertuzumab administer load dose 840mg iv , 420mg iv 3-weekly , Herceptin load dose 8mg/kg iv 6mg/kg 3-weekly , docetaxel dose 75mg/m2 escalate 100mg/m2 3-weekly . During entire pre- post-surgery period patient receive adequate chemotherapy per standard care , well surgery and/or radiotherapy require . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Pertuzumab Combination With Herceptin Patients With HER2 Positive Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>female patient , &gt; =18 year age ; locally advance , inflammatory early stage invasive breast cancer ; HER2 positive ( HER2+++ IHC FISH/CISH+ ) . metastatic disease ( Stage IV ) bilateral breast cancer ; previous anticancer therapy radiotherapy malignancy ; malignancy , cancer situ cervix , basal cell cancer ; insulindependent diabetes ; clinically relevant cardiovascular disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>